RE:Q1 ResultsI think these are great results. Biorem was headed for a great year if COVID hadn't have hit. Although they may still come out of this year similar to last year.
Highlights I see from the report:
- Cash grew again and with AR at $6.265 million there is more cash to come
- Still zero debt on the books
- Revenue in the quarter was the 3rd highest since Q1 2015 and Q1 not traditionally a good quarter for revenue
- Operating costs are way down from previous quarter and Q1 2019
- Pro and con is that China revenue was really low this quarter so if we start cashing in on business there while keeping our north american revenues at this level we are in for some good income numbers
- Order bookings were lower this quarter but understantable considering the ecomony
- Order backlog is at a record amount
Definitely at least holding my shares and considering purchasing more at anything under $.35
GLTA